Revolutionary new treatment for multidrug-resistant tuberculosis
Lancet Infect Dis
.
2019 Jun;19(6):576-577.
doi: 10.1016/S1473-3099(19)30216-6.
Authors
Sarah Meredith
1
,
Andrew Nunn
2
,
I D Russen
3
Affiliations
1
MRC Clinical Trials Unit at UCL, University College London, London WC1V 6LJ, UK. Electronic address: s.meredith@ucl.ac.uk.
2
MRC Clinical Trials Unit at UCL, University College London, London WC1V 6LJ, UK.
3
Vital Strategies, New York, NY, USA.
PMID:
31122770
DOI:
10.1016/S1473-3099(19)30216-6
No abstract available
Publication types
Letter
Comment
MeSH terms
Antitubercular Agents
Humans
Tuberculosis, Multidrug-Resistant*
Substances
Antitubercular Agents